ArticleBMC cancer2021

Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort.

Rafaela Pirolli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.